Alnylam Pharmaceuticals, Inc.
(NASDAQ : ALNY)

( )
ALNY After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 6.17%76.981.0%$1926.97m
AMGNAmgen, Inc. 5.60%208.881.3%$915.32m
REGNRegeneron Pharmaceuticals, Inc. 0.42%498.752.6%$847.19m
BIIBBiogen, Inc. 3.82%304.471.5%$744.46m
VRTXVertex Pharmaceuticals, Inc. 7.40%242.161.9%$592.84m
MRNAModerna, Inc. 11.90%33.200.0%$552.46m
ILMNIllumina, Inc. 6.45%272.993.5%$473.01m
ALXNAlexion Pharmaceuticals, Inc. 0.47%90.352.0%$283.66m
AAgilent Technologies, Inc. 4.95%72.331.6%$222.85m
INCYIncyte Corp. 3.90%77.072.5%$183.14m
EXASEXACT Sciences Corp. 3.08%57.6021.0%$182.24m
BMRNBioMarin Pharmaceutical, Inc. 2.96%86.064.3%$164.43m
SGENSeattle Genetics, Inc. 6.68%118.676.1%$161.87m
NVAXNovavax, Inc. -1.21%13.86114.7%$117.94m
SRPTSarepta Therapeutics, Inc. 3.20%95.9814.0%$98.31m

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.